Semax

What Semax is

Semax (Met-Glu-His-Phe-Pro-Gly-Pro; MEHFPGP) is a synthetic heptapeptide derived from the 4–10 fragment of adrenocorticotropic hormone (ACTH). It was developed beginning in the late 1970s at the Institute of Molecular Genetics of the Russian Academy of Sciences, under a program led by Academicians Nikolai Myasoedov and Igor Ashmarin of Moscow State University [1, 2]. The foundational observation driving the program was that ACTH fragments — particularly the 4–7 and 4–10 residue sequences — possessed potent nootropic and neurotrophic activity that was entirely independent of the adrenal hormonal effects associated with full-length ACTH(1-39) ^[3]. The native ACTH(4-10) fragment was, however, rapidly degraded by serum carboxypeptidases, making practical pharmaceutical development difficult ^[1].

The key engineering breakthrough was the addition of a Pro-Gly-Pro (PGP) tripeptide to the C-terminus of the active ACTH(4-7) core. Proline-rich termini are known to resist exopeptidase attack, and this modification extended the peptide's enzymatic stability markedly, giving it meaningful pharmacokinetic properties when delivered intranasally [1, 2]. The resulting compound — Semax — is classified as a melanocortin-related regulatory peptide and is entirely devoid of the hormonal (corticotropic) activity of native ACTH [3, 4]. Semax was registered as a prescription pharmaceutical in Russia and has approved indications there including cognitive impairment, ischemic stroke recovery, and optic nerve disease ^[2]. It is not approved by the FDA in the United States or by the EMA in Europe.

What it is being researched for

1. Neuroprotection in ischemic stroke

The largest body of clinical research on Semax concerns its potential to protect brain tissue during and after ischemic stroke. The synthetic peptide has been shown to effectively protect the brain against ischemic stroke in preclinical models ^[4]. At the molecular level, Semax has been found to suppress the expression of pro-inflammatory genes (such as Hspb1, Fos, IL-1b, IL-6, Ccl3, and Socs3) and simultaneously activate genes associated with neurotransmission in rat transient middle cerebral artery occlusion (tMCAO) models ^[5]. Genome-wide transcriptome analysis revealed that Semax modulates both immune and vascular gene expression pathways in the ischemized brain cortex ^[6]. A non-randomized open-label clinical study in 110 post-stroke patients reported elevated plasma BDNF levels and improvements in functional outcome measures compared with a non-Semax comparator group, though the trial lacked randomization, placebo control, and full statistical reporting, limiting interpretation of the findings ^[7].

2. Cognitive enhancement and nootropic activity

Semax is classified as a nootropic peptide, and its cognitive effects have been investigated across cell cultures, rodent behavioral models, and some human studies. In rodent models, Semax has been shown to facilitate acquisition of active avoidance behavior and improve performance in learning and memory tasks ^[8]. The peptide upregulates both BDNF mRNA and protein in the hippocampus, a brain region critical for memory consolidation, with the modulation staying within the physiological range and appearing to be region-specific — effects were not observed in the cerebellum ^[8]. Studies have also demonstrated Semax activates neurotrophic genes and their receptors in cell cultures and in the hippocampus and frontal cortex of intact animals ^[9]. Clinical observations in Russia have documented benefits for patients with cognitive impairment from stroke, brain injury, and age-related decline, though independent Western replication of these human findings remains limited ^[7].

3. BDNF and neurotrophin regulation

One of the most replicated findings in Semax research is its capacity to modulate neurotrophin expression. Studies have demonstrated that Semax increases the expression of mRNA for both NGF (nerve growth factor) and BDNF in cultures of nerve and glial cells ^[9]. In the rat hippocampus, Semax application produces increases in BDNF mRNA levels, BDNF protein levels, and phosphorylation of the TrkB receptor — the primary high-affinity receptor for BDNF ^[8]. Time-course analyses in rat hippocampus and frontal cortex showed that BDNF and NGF gene expression changes develop in a region-specific and time-specific pattern following Semax application, ultimately producing rapid, long-term, and specific activation of neurotrophin expression ^[10]. Because BDNF is known to drive downstream pathways including MAPK/ERK, PI3K/Akt, and PLC-gamma — all of which support neuronal survival, synaptic plasticity, and memory formation — upregulation of this system is considered a central mechanistic node for Semax's observed cognitive and neuroprotective effects [8, 9].

4. Monoaminergic system modulation

Beyond neurotrophin pathways, research has examined how Semax interacts with the brain's dopaminergic and serotonergic systems. Rodent studies found that Semax produces a significant increase in the tissue and extracellular content of the serotonin metabolite 5-HIAA in the striatum, indicating activation of the serotonergic system ^[3]. While Semax alone did not directly alter tissue concentrations of dopamine or its metabolites, it dramatically enhanced the striatal release of dopamine and locomotor activity induced by D-amphetamine when co-administered, revealing a potent modulatory effect on dopaminergic tone ^[3]. These findings suggest Semax may influence mood, motivation, and attentional states through monoaminergic pathways in addition to its neurotrophin effects [3, 9].

5. Optic nerve protection

Semax has been investigated as a neuroprotective agent for optic nerve diseases, consistent with its broader neurotrophin-upregulating and anti-inflammatory profile. Clinical studies in Russia examined the peptide in patients with vascular, toxic-allergic, and inflammatory diseases of the optic nerve, as well as partial atrophy of the optic nerve, alongside basic neurotrophic and anti-inflammatory therapy ^[11]. In a study of glaucoma patients with normalized intraocular pressure, electrophysiological and computer-based examination methods demonstrated advantages of Semax-containing neuroprotective therapy over traditional neuroprotective treatment ^[12]. Researchers attributed the efficacy to Semax's combined neuroprotective and neurotrophic properties acting on the pathogenesis of optic neuropathy ^[12]. Research in this area remains predominantly Russian-language, published in ophthalmology journals, and has not been extensively replicated in international controlled trials.

6. Neuroinflammation and immune gene regulation

A growing line of research focuses on how Semax modulates the brain's immune response during neurological injury. Transcriptome analysis in rat models of focal cerebral ischemia showed that the peptide predominantly enhanced expression of immune system-related genes, with effects growing considerably more pronounced at 24 hours after permanent middle cerebral artery occlusion compared with three hours ^[6]. A separate study using RNA-Seq in the tMCAO model found that Semax suppressed expression of inflammatory genes while activating those associated with neurotransmitter signaling ^[5]. Analysis of key proteins in the ischemia-reperfusion model indicated that Semax modulated MMP-9, c-Fos, JNK (markers of inflammation and cell death), and CREB (a marker of neuroprotection and recovery) ^[13]. Researchers have proposed that the neuroprotective mechanism of Semax is realized in part through neuroimmune crosstalk ^[4].

7. Alzheimer's disease and amyloid pathology

More recent preclinical work has explored whether Semax and its derivatives could have relevance to Alzheimer's disease research. In a study using the APPswe/PS1dE9 transgenic mouse model — a standard preclinical model of Alzheimer's-type amyloidosis — Semax and a heptapeptide derivative were assessed on both behavioral and histological outcomes ^[14]. Behavioral testing using open field, novel object recognition, and Barnes maze paradigms demonstrated that Semax improved cognitive functions in the mice ^[14]. Histological examination of brain tissue showed that Semax significantly reduced the number of amyloid inclusions in both the cortex and hippocampus ^[14]. These findings are preliminary and have not been replicated in independent studies or in human participants; substantial further research would be needed before any translational conclusions could be drawn.

How it is thought to work

Semax is understood to work through several overlapping biological pathways rather than a single receptor target. At the neurotrophin level, Semax upregulates the expression of BDNF and its receptor TrkB in the hippocampus and frontal cortex [8, 9]. Activation of TrkB by BDNF in turn recruits downstream survival and plasticity pathways — including MAPK/ERK, PI3K/Akt, and PLC-gamma — which support neuronal survival, synaptic strength, and memory encoding ^[8]. This effect appears to be brain region-specific; for example, robust changes in hippocampal BDNF levels are not mirrored in the cerebellum, suggesting anatomically selective signaling rather than a non-specific global effect ^[8]. Semax has also been found to bind to specific sites in the rat basal forebrain with measurable affinity, indicating the presence of discrete binding targets, though the receptor pharmacology has not been fully characterized ^[9].

At the neuroinflammatory level, Semax suppresses gene expression associated with inflammatory cytokine cascades (including IL-1b, IL-6, and related stress-response genes) while simultaneously activating neurotransmitter-associated gene expression in ischemic brain tissue [5, 6]. Additionally, Semax has been shown to promote survival of neurons during hypoxia and glutamate-induced excitotoxicity, contribute to mitochondrial stability under calcium-dysregulation stress, and inhibit nitric oxide synthesis — all of which would theoretically reduce secondary brain injury following ischemic events ^[15]. Within the monoaminergic system, Semax produces positive modulatory effects on striatal serotonin turnover and sensitizes dopaminergic neurons to stimulation ^[3]. Taken together, current research characterizes Semax as a multi-target peptide whose effects converge on neurotrophin signaling, neuroinflammatory modulation, and monoaminergic tone.

Where the evidence stands

The preclinical evidence base for Semax is relatively robust. Studies in rodent cell cultures, hippocampal slice preparations, and whole-animal models have consistently demonstrated its capacity to upregulate BDNF/TrkB signaling, improve performance on learning and memory tasks, and reduce markers of ischemic injury in stroke models [3, 5, 6, 8, 10]. Genome-wide transcriptomics in rat models have identified hundreds of differentially expressed genes in response to Semax treatment, providing mechanistic depth to the observed neuroprotective effects [5, 6, 13]. A mouse Alzheimer's disease model study further showed reductions in amyloid plaque burden alongside improved behavioral outcomes ^[14]. These preclinical findings are consistent across multiple research groups and provide a coherent mechanistic framework.

Human clinical evidence is considerably more limited. Most human trials have been conducted in Russia, often in open-label or non-randomized designs, in populations with neurological injury (primarily ischemic stroke) rather than in healthy participants ^[7]. One frequently cited non-randomized, non-placebo-controlled Russian clinical study in 110 post-stroke patients reported improvements in functional outcome scores and elevated plasma BDNF, but without published confidence intervals or p-values in the abstract, limiting independent assessment ^[7]. The evidence for cognitive effects in healthy humans is essentially absent from the peer-reviewed literature. Independent replication by Western research groups has not occurred at scale, and there are no large randomized controlled trials registered with international registries (ClinicalTrials.gov) as of the time of writing. The long-term safety profile of Semax in humans is also not established from published controlled data. Researchers should treat any extrapolation from animal studies to human populations with significant caution.

Frequently asked questions

What is Semax and where does it come from?

Semax is a synthetic heptapeptide developed in Russia in the early 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences. It was engineered from the 4–10 fragment of adrenocorticotropic hormone (ACTH) with a stabilizing Pro-Gly-Pro tail added to improve its enzymatic stability. It is classified as a melanocortin-related regulatory peptide with nootropic and neuroprotective properties studied in preclinical and some clinical research.

Does Semax act like ACTH and affect hormones?

No. Although Semax is derived from the ACTH(4-10) fragment, it is entirely devoid of the hormonal (corticotropic) activity of full-length ACTH. It does not stimulate the adrenal glands or drive cortisol production. This separation of cognitive and neuroprotective activity from hormonal activity was one of the primary goals of its design.

What does the research say Semax does to BDNF?

Preclinical research consistently shows that Semax upregulates BDNF (brain-derived neurotrophic factor) mRNA and protein levels, particularly in the hippocampus and frontal cortex. It also increases phosphorylation of the TrkB receptor, which is BDNF's primary high-affinity receptor. These effects have been observed in both cell culture and rodent models, and the increase appears to remain within the physiological range.

Has Semax been tested in human clinical trials?

Yes, but the human clinical evidence is limited and mostly comes from Russia. The strongest human data relates to neuroprotection following ischemic stroke, where non-randomized and some controlled studies have reported improvements in functional outcomes. Most trials were conducted in Russia, often with design limitations such as lack of placebo control or full statistical reporting, and independent Western replication has not occurred at scale.

Is Semax approved by the FDA or Health Canada?

Semax is not approved by the FDA in the United States or by Health Canada. It has been registered as a prescription pharmaceutical in Russia with approved indications that include ischemic stroke recovery, cognitive impairment, and optic nerve disease. Researchers outside Russia work with it as an investigational research compound.

What brain systems does Semax affect beyond BDNF?

Research in rodents indicates that Semax modulates serotonergic activity in the striatum, significantly increasing turnover of the serotonin metabolite 5-HIAA. It also sensitizes dopaminergic neurons, enhancing the dopamine-releasing effect of stimulants in animal models. Additionally, Semax suppresses neuroinflammatory gene expression and inhibits nitric oxide synthesis in the ischemic brain.

Has Semax been studied for Alzheimer's disease?

Preliminary preclinical research has examined Semax in a transgenic mouse model of Alzheimer's-type amyloidosis (APP/PS1 mice). The study found improvements in behavioral cognitive tests and reductions in amyloid plaque burden in brain tissue. However, these are early animal findings and have not been replicated in human clinical trials; no conclusions about efficacy in Alzheimer's disease in humans can be drawn from the current evidence.

What are the known limitations of Semax research?

The primary limitations are that most human clinical trials were conducted in Russia with methodological constraints (non-randomized, non-placebo-controlled, limited statistical reporting), that independent Western replication is largely absent, and that long-term safety data from controlled human studies are not established. Most mechanistic and efficacy data come from cell and animal models, which may not translate directly to humans.

What is the Pro-Gly-Pro (PGP) tail in Semax and why does it matter?

The Pro-Gly-Pro tripeptide was added to the C-terminus of the ACTH(4-7) core to resist enzymatic degradation by serum carboxypeptidases. Without this modification, the native ACTH fragment would be broken down very rapidly, making it pharmacologically impractical. PGP extends Semax's enzymatic stability significantly and is considered the key structural feature enabling its practical use in research.

What is Semax being studied for in optic nerve research?

Russian clinical studies have investigated Semax as a neuroprotective agent for optic nerve diseases including glaucomatous optic neuropathy and inflammatory and vascular diseases of the optic nerve. Early studies reported improvements in visual function measures, attributed to Semax's combined neuroprotective and neurotrophic effects. This research area remains limited to Russian-language publications and has not been validated in large international controlled trials.

Glossary

ACTH (Adrenocorticotropic hormone)

A pituitary hormone that normally stimulates the adrenal cortex to produce cortisol; Semax is derived from a short fragment of ACTH (residues 4–10) that lacks this hormonal activity.

BDNF (Brain-derived neurotrophic factor)

A protein that supports the survival, growth, and differentiation of neurons and is considered a key mediator of synaptic plasticity and memory formation.

TrkB receptor

The primary high-affinity receptor for BDNF; when activated by BDNF, it triggers downstream signaling cascades including MAPK/ERK and PI3K/Akt that promote neuronal survival and plasticity.

Nootropic

A compound studied for its potential to support cognitive functions such as learning, memory, and attention without producing significant sedation or toxicity at research doses.

Melanocortin

A family of peptides derived from proopiomelanocortin (POMC), including ACTH and alpha-MSH, which bind to melanocortin receptors and have wide-ranging neurological, immune, and endocrine effects.

tMCAO (Transient middle cerebral artery occlusion)

A standard rodent model of ischemic stroke in which the middle cerebral artery is temporarily blocked to simulate the brain injury that occurs during a human ischemic stroke.

Pro-Gly-Pro (PGP) tripeptide

A three-amino-acid sequence (proline-glycine-proline) appended to the C-terminus of Semax to confer resistance to enzymatic degradation and extend the peptide's biological stability.

Neuroinflammation

An inflammatory response occurring within the brain or spinal cord, mediated by immune cells such as microglia and astrocytes, which plays a critical role in both acute brain injury and chronic neurodegenerative diseases.

References

1. Semax: Discovery and Regulatory History (Sparta Labs) — Sparta Labs educational reference / historical synthesis
2. Semax (ACTH(4-7)-PGP): History, pharmacology and approved indications — PeptideList.org educational reference
3. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents — Neurochemical Research (PubMed PMID: 16362768)
4. Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats — Molecular Genetics and Genomics (PubMed PMID: 28255762)
5. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia–Reperfusion — PMC / Frontiers in Neuroscience (PMC8226508)
6. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis — PMC / BMC Genomics (PMC3987924)
7. Semax: An ACTH(4-7)-Derived Heptapeptide and Melanocortin Receptor Modulator — Clinical Evidence Review — Superpower.com research guide (synthesis of published Russian clinical literature)
8. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus — Brain Research (PubMed PMID: 16904115; DOI: 10.1016/j.brainres.2006.07.108)
9. Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain — Journal of Neurochemistry (DOI: 10.1111/j.1471-4159.2006.03658.x)
10. Effect of semax on the temporal dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex — Zhurnal Vysshei Nervnoi Deyatelnosti (PubMed PMID: 18756821)
11. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease (Polunin et al., 2000) — Vestnik Oftalmologii (PubMed PMID: 10741256)
12. Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone (Kurysheva et al., 2001) — Vestnik Oftalmologii (PubMed PMID: 11569188)
13. Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries — PMC / International Journal of Molecular Sciences (PMC10218113)
14. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease — Acta Naturae / PubMed (PMID: 41479572; PMC: PMC12755871)
15. Semax: Neuroprotection and neurotrophin mechanisms (PMC summary, Medvedeva et al. context) — PMC / BMC Genomics (PMC3987924) — cited for neuroprotection mechanism detail